[go: up one dir, main page]

AU2001232736A1 - Protein c derivatives - Google Patents

Protein c derivatives

Info

Publication number
AU2001232736A1
AU2001232736A1 AU2001232736A AU3273601A AU2001232736A1 AU 2001232736 A1 AU2001232736 A1 AU 2001232736A1 AU 2001232736 A AU2001232736 A AU 2001232736A AU 3273601 A AU3273601 A AU 3273601A AU 2001232736 A1 AU2001232736 A1 AU 2001232736A1
Authority
AU
Australia
Prior art keywords
derivatives
wild
protein
human protein
type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001232736A
Inventor
Bruce Edward Gerlitz
Bryan Edward Jones
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2001232736A1 publication Critical patent/AU2001232736A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood
    • Y10S530/83—Plasma; serum

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Novel human protein C derivatives are described. These derivatives have increased anti-coagulation activity and resistance to inactivation by serpins, compared to wild-type protein C and retain the biological activity of the wild-type human protein D. These derivatives will require either less frequent administration and/or smaller dosage than wild-type human protein C in the treatment of acute coronary syndromes, vascular occlusive disorders, hyper coagulable states, thrombotic disorders and disease states predisposing to thrombosis.
AU2001232736A 2000-02-02 2001-01-19 Protein c derivatives Abandoned AU2001232736A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US17980100P 2000-02-02 2000-02-02
US60179801 2000-02-02
US18919700P 2000-03-14 2000-03-14
US60189197 2000-03-14
PCT/US2001/000020 WO2001057193A2 (en) 2000-02-02 2001-01-19 Protein c derivatives

Publications (1)

Publication Number Publication Date
AU2001232736A1 true AU2001232736A1 (en) 2001-08-14

Family

ID=26875697

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001232736A Abandoned AU2001232736A1 (en) 2000-02-02 2001-01-19 Protein c derivatives

Country Status (9)

Country Link
US (1) US6841371B2 (en)
EP (1) EP1255821B1 (en)
JP (1) JP2003521919A (en)
AT (1) ATE286122T1 (en)
AU (1) AU2001232736A1 (en)
CA (1) CA2399267A1 (en)
DE (1) DE60108076T2 (en)
ES (1) ES2234807T3 (en)
WO (1) WO2001057193A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2399267A1 (en) 2000-02-02 2001-08-09 Eli Lilly And Company Protein c derivatives
CA2400187A1 (en) 2000-02-11 2001-08-16 Eli Lilly And Company Protein c derivatives
US6933367B2 (en) 2000-10-18 2005-08-23 Maxygen Aps Protein C or activated protein C-like molecules
EP1483380A2 (en) * 2002-03-01 2004-12-08 T.A.C. Thrombosis and Coagulation AB Recombinant protein c variants
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
CA2574598A1 (en) * 2004-07-23 2006-02-09 The University Of Rochester Activated protein c inhibits undesirable effects of plasminogen activator in the brain
ZA200800251B (en) * 2005-06-24 2009-04-29 Drugrecure Aps Airway administration of tissue factor pathway inhibitor in inflammatory conditions affecting the respiratory track
EP2242875A4 (en) * 2008-01-15 2012-04-04 Univ British Columbia PROTEIN C RS2069915 AS A SURVIVOR RESPONSE PREDICTOR AND ADMINISTRATION OF PROTEIN C OR AN ACTIVE PROTEIN C COMPOUND
WO2012068519A2 (en) 2010-11-19 2012-05-24 Sirius Genomics Inc. Markers associated with response to activated protein c administration, and uses thereof
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT87688B (en) 1987-06-12 1992-09-30 Hoechst Japan PROCESS FOR THE PREPARATION OF HYBRID PROTEIN C
US4992373A (en) 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
US5196322A (en) 1987-12-28 1993-03-23 Eli Lilly And Company Vectors and compounds for expression of zymogen forms of human protein C
JPH0246296A (en) 1988-08-09 1990-02-15 Hoechst Japan Ltd Hybrid protein c and production thereof
JP2774154B2 (en) * 1989-08-10 1998-07-09 帝人株式会社 Activated human protein C derivative
AU7168591A (en) * 1989-12-29 1991-07-24 Zymogenetics Inc. Hybrid protein c
US5358932A (en) 1989-12-29 1994-10-25 Zymogenetics, Inc. Hybrid protein C
US5270178A (en) 1990-02-23 1993-12-14 Eli Lilly And Company Vectors and compounds for expression of zymogen forms of human protein C
IL97311A0 (en) 1990-02-23 1992-05-25 Lilly Co Eli Vectors and compounds for expression of glycosylation mutants of human protein c
MY110664A (en) * 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
US5847085A (en) 1996-11-08 1998-12-08 Oklahoma Medical Research Foundation Modified protein C and methods of use thereof
US5837843A (en) 1996-11-08 1998-11-17 Oklahoma Medical Research Foundation Modified protein C
SE9701228D0 (en) * 1997-04-03 1997-04-03 Bjoern Dahlbaeck Recombinant protein C and protein S variants
US6017882A (en) 1997-10-23 2000-01-25 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
KR20010053345A (en) * 1999-04-30 2001-06-25 피터 지. 스트링거 Protein C Derivatives
JP2003514545A (en) * 1999-11-19 2003-04-22 イーライ・リリー・アンド・カンパニー Protein C derivative
CA2399267A1 (en) 2000-02-02 2001-08-09 Eli Lilly And Company Protein c derivatives
CA2400187A1 (en) 2000-02-11 2001-08-16 Eli Lilly And Company Protein c derivatives
WO2001072328A2 (en) 2000-03-28 2001-10-04 Eli Lilly And Company Methods of treating diseases with activated protein c
AU2002235073B2 (en) 2001-03-02 2007-02-01 T.A.C. Thrombosis And Coagulation Ab Protein C variants

Also Published As

Publication number Publication date
DE60108076D1 (en) 2005-02-03
US20030207435A1 (en) 2003-11-06
EP1255821A2 (en) 2002-11-13
CA2399267A1 (en) 2001-08-09
ATE286122T1 (en) 2005-01-15
ES2234807T3 (en) 2005-07-01
WO2001057193A2 (en) 2001-08-09
DE60108076T2 (en) 2006-03-16
WO2001057193A3 (en) 2002-02-07
EP1255821B1 (en) 2004-12-29
JP2003521919A (en) 2003-07-22
US6841371B2 (en) 2005-01-11

Similar Documents

Publication Publication Date Title
ATE314116T1 (en) USE OF ROXITHROMYCIN FOR PRODUCING A MEDICATION TO IMPROVE THE BIOLOGICAL AND ANTIVIRAL ACTIVITY OF PROTEASE INHIBITORS
NO963568D0 (en) Pharmaceutical composition for the treatment of blood coagulation disorders, methods for the preparation thereof and its use
CY1107248T1 (en) SUSPENED PROTEINS
WO2005055944A3 (en) Oligosaccharide compositions and use thereof in the treatment of infection
ATE257390T1 (en) USE OF A BPI PROTEIN PRODUCT AS AN ANTITHRBOTIC AGENT
ATE531382T1 (en) TREATMENT METHODS OF INFLAMMATORY DISEASES WITH ACTIVE INGREDIENTS SPECIFICALLY BINDING TO HUMAN ANGIOPOIETIN-2
WO1998033509A3 (en) Useful properties of human lactoferrin and variants thereof
AU2001232736A1 (en) Protein c derivatives
DE69331739D1 (en) INNOVATIVE PHARMACEUTICAL USES OF KRILL ENZYMS
ATE353366T1 (en) NUCLEIC ACID AND PROTEIN, CALLED 158P1D7, FOR THE TREATMENT AND DETECTION OF BLADDER CANCER AND OTHER TYPES OF CANCER
AU2742892A (en) An anticoagulant substance obtained from urine
DE69719754D1 (en) THERAPEUTIC USE OF BPI PROTEIN PRODUCTS IN PEOPLE WITH BREEDING THROUGH TRAUMA
EP1544214A4 (en) ANTI-APC NON-NEUTRALIZING ANTIBODIES
WO2001036462A3 (en) Protein c derivatives
WO1999058098A3 (en) HUMAN ANTITHROMBIN IIIs AND METHODS RELATED THERETO
BR0006088A (en) Protein derivatives c
WO2005042699A3 (en) Modified polypeptides with therapeutic activity and methods of use
DE50009838D1 (en) HUMAN ANTIBIOTIC PROTEIN
WO2004056768A3 (en) Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
WO2001089558A3 (en) Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states
DE59909356D1 (en) PHARMACEUTICAL PREPARATION CONTAINING A RECEPTOR ANTAGONIST FOR THE TREATMENT OF BLOOD COagulation disorders
EE200300506A (en) Preparations of 3,7-diazabicyclo [3.3.1], methods for their preparation and their use in the prophylaxis or treatment of cardiac arrhythmias
ZA200205880B (en) Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith.
DE60135232D1 (en) NUCLEIC ACID AND CORRESPONDING PROTEIN 85P1B3, USEFUL FOR THE TREATMENT AND DETECTION OF CANCER DISORDERS
DE69113049D1 (en) VARIANTS OF THE TISSUE PLASMINOGEN ACTIVATOR WITH REDUCED DISASSEMBLY.